Rivaroxaban for Stroke Prevention in Hypertrophic Cardiomyopathy Without Atrial Fibrillation and With Impaired Left Atrial Reservoir Strain: Design and Rationale of the LA-HCM Randomized Trial

Clicks: 11
ID: 331855
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #144 of 157 articles by views in European Heart Journal - Cardiovascular Imaging

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 157 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
BACKGROUND: Current stroke prevention strategies in hypertrophic cardiomyopathy (HCM) rely on the detection of atrial fibrillation (AF), although thromboembolic events may occur before arrhythmia is documented. These observations support atrial cardiomyopathy as the substrate for thrombogenesis and highlight the need for imaging-guided risk stratification. Left atrial reservoir strain (LARS), derived from speckle-tracking echocardiography, detects atrial dysfunction earlier than left atrial enlargement and has been associated with AF and thromboembolic events. The LA-HCM trial evaluates whether rivaroxaban reduces thromboembolic events in patients with HCM, sinus rhythm, no documented AF, and impaired LARS. LA-HCM is a prospective, multicentre, randomized, open-label trial with blinded endpoint adjudication (PROBE design), sponsored by Rennes University Hospital and conducted in 17 French centres. A total of 532 adults with HCM, sinus rhythm, no documented AF, and core-laboratory-confirmed LARS ≤20% are randomized 1:1 to rivaroxaban or standard care. Participants are followed for 24 months. The primary endpoint is the composite of all-cause death, myocardial infarction, ischemic stroke-including newly detected silent cerebral infarction on paired baseline and 24-month brain MRI-and systemic embolism at 24 months. LA-HCM tests whether rivaroxaban improves outcomes in a population with HCM, no documented AF, and impaired LARS. It evaluates a LARS-based treatment-allocation strategy but is not designed to validate the predictive utility or optimal threshold of LARS.
Reference Key
openalex_W7220893445 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Erwan Donal, Adrien Al Wazzan, Olivier Lairez, Philippe Charron, Nicolas Piriou, Loïc Bière, Patricia Réant, Ombeline Paglia, Fabien Labombarda, Jean‐Christophe Eicher, Gilles Barone‐Rochette, Hélène Ridon, Gilbert Habib, Olivier Huttin, Nadia Aïssaoui, Damien Logeart, Charles Fauvel, Nathan Mewton, Elena Galli, Eve Cariou, Anne Bernard, Jean-François Hulot, Laurent Fauchier, Pascale Palassin, Jean‐Christophe Ferré, Anne Ganivet, Alexandre Mansour, Emmanuel Oger
Are you one of these authors? Claim your profile
Journal European Heart Journal - Cardiovascular Imaging
Year 2026
DOI
10.1093/ehjci/jeag280
URL
https://doi.org/10.1093/ehjci/jeag280
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.